Clinical trials: Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

• Recruiting
• Age: 10 to 17 years
• Phase 2

This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and < 18 years.

Trial name

FENerations1 (NCT07161258)

Testing

Fenebrutinib

Where

17 sites in Argentina, Brazil and 5 more

Volunteers

12 people

Sponsor

Hoffmann-La Roche